Status:
RECRUITING
Effect of Genetic Polymorphisms on the Clinical Response to SGLT2 Inhibitors in Heart Failure Patients
Lead Sponsor:
October 6 University
Collaborating Sponsors:
University of Florida
National Heart Institute, Egypt
Conditions:
Genetic Polymorphisms
Heart Failure
Eligibility:
All Genders
18-80 years
Brief Summary
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown further reductions in heart failure hospitalization, cardiovascular events, and mortality, especially for heart failure patients. The SGLT...
Detailed Description
Sodium-glucose cotransporter-2 inhibitors (SGLT-2i), which were first investigated and licensed for the treatment of diabetes, are now emerging as a promising class of drugs for the treatment of heart...
Eligibility Criteria
Inclusion
- Heart failure patients NYHA class II to III.
- Heart failure patients with reduced left ventricular ejection fraction (LVEF) \< 45% or with preserved left ventricular ejection fraction (LVEF) \> 45%
- Patients who will be candidate for add-on treatment with SGLT2.
- Patients who will be able to sign informed consent to participate in the study.
Exclusion
- Contraindications to SGLT2.
- Significant coronary artery diseases (CAD), coronary artery bypass grafting (CABG), percutaneous coronary intervention (PCI), or valve surgery within 3 months.
- Pregnant or breastfeeding women.
- Patients with estimated glomerular filtration rates less than 30 mL/min/1.73 m2, as determined using the CKD-EPI equation.
Key Trial Info
Start Date :
December 27 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2024
Estimated Enrollment :
282 Patients enrolled
Trial Details
Trial ID
NCT06201000
Start Date
December 27 2023
End Date
September 1 2024
Last Update
February 7 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Florida
Gainesville, Florida, United States, 32610